| abstract |
The invention firstly provides a type of novel dibenzocyclooctene lignan derivatives, which have the following structural formula; the dibenzocyclooctene lignan derivatives are screened through the suppression test to HBVs antigen and e-antigen secreted by a cell model-hepatitis B virus (HBV) transfected HepG2 cells (that is HepG2.2.2.15 cells), most of the compounds are found to have a certain suppression role, wherein a plurality of specific compounds represent the relatively good activity and represent the stable therapeutic effect during a plurality of rounds of experiments. Based on this, the novel dibenzocyclooctene lignan derivatives constitute a type of molecules with anti-HBV bioactivity and are expected to be used in the preparation of anti-HBV drugs. |